Dr Oleg Anichtchik

Dr Oleg Anichtchik

Honorary Lecturer in Clinical Neurobiology

Faculty of Health

Oleg can be contacted through arrangement with our Press Office, to speak to the media on these areas of expertise.
  • Alzheimer's disease
  • Dementia
  • Dementia clinical trials


2013 - present - Principal Investigator, Lecturer, Department of Clinical Neurobiology, Plymouth University Schools of Medicine and Dentistry.            



2001 - Ph.D. degree was awarded by the Faculty of Mathematics and Natural Sciences, Åbo Akademi University, Turku, Finland;

1996 - M.D. degree was awarded by the Faculty of the General Medicine, Grodno State Medical Institute, Grodno, Belarus. 

Previously held positions:

2010 - 2013 -
Alzheimer Research UK (ARUK) Senior Research fellow, Centre for Brain Repair, University of Cambridge, United Kingdom ;

2009 - 2012 - Clare College Research Associate, University of Cambridge, United Kingdom ;

2007-2010 - Postdoctoral fellow at Cambridge Centre for Brain Repair, University of Cambridge, United Kingdom;  

2005 - 2007 - Senior Research Associate, Daniolabs Ltd, Cambridge, United Kingdom;

2001 - 2004 - Finnish Academy of Sciences postdoctoral fellow, Institute of Biomedicine, Department of Anatomy, University of Helsinki, Finland;

1995 - 1996 - Junior researcher at the Laboratory of Morphology and Neurochemistry, Institute of Biochemistry, Academy of Sciences of Belarus, Grodno, Belarus.   

Professional membership

Fellow of the Higher Education Academy, UK; 

Member of the Society for Neuroscience, USA;

Member of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), USA.   

Research interests

Understanding mechanisms of insoluble protein aggregates formation and cellular degeneration in the human brain is one of the most pressing questions of clinical neurobiology. We are trying to understand the process of alpha-synuclein aggregation in the development of neurodegenerative disorders such as Parkinson's disease and dementia with Lewy bodies. In particular, we are looking for the reasons of a selective vulnerability of neurons to the toxic insult caused by aggregating proteins and whether dis-aggregating strategies could be beneficial in these conditions.  To address this, classical neuromorphology, biochemistry and cell biology techniques are used in the range of in vitro and in vivo models, including human post-mortem studies, animal models of neurodegeneration and cell culture assays.

Grants & contracts

2016 -        Alzheimer’s Research UK network centre grant, £25,000 (PI)

2016 -        BRACE Alzheimer's Research, £86,000 (PI)

2016 -        Northcott Devon Medical Foundation (UK), £7,000 (PI)

2015 -        British Neuropathological Society, £5,000 (PI)

2014 -        Alzheimer’s Research UK network centre grant , £25,000 (PI)

Research groups

Key publications are highlighted

Li X, Wang H, Long J, Pan G, He T, Anichtchik O, Belshaw R, Albani D, Edison P & Green EK 2018 'Systematic Analysis and Biomarker Study for Alzheimer's Disease' Scientific Reports 8, Author Site , DOI PEARL
Jackson J, Bianco G, Rosa AO, Cowan K, Bond P, Anichtchik O & Fern R 2018 'White matter tauopathy: Transient functional loss and novel myelin remodeling' Glia Author Site , DOI PEARL
Evans T, Kok WL, Cowan K, Hefford M & Anichtchik O 2017 'Accumulation of beta-synuclein in cortical neurons is associated with autophagy attenuation in the brains of dementia with Lewy body patients' Brain Research 1681, 1-13 , DOI PEARL
Hall K, Yang S, Sauchanka O, Spillantini MG & Anichtchik O 2015 'Behavioural deficits in transgenic mice expressing human truncated (1-120 amino acid) alpha-synuclein' Experimental Neurology 264, 8-13 Author Site , DOI
Malek N, Swallow D, Grosset KA, Anichtchik O, Spillantini M & Grosset DG 2014 'Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review' Acta Neurologica Scandinavica 130, (2) 59-72 Author Site , DOI
Anichtchik O, Calo L & Spillantini MG 2013 'Synaptic dysfunction in synucleinopathies' CNS Neurol Disord Drug Targets 12, (8) 1094-1100 Author Site
Garcia-Reitboeck P, Anichtchik O, Dalley JW, Ninkina N, Tofaris GK, Buchman VL & Spillantini MG 2013 'Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra' Exp Neurol 248, 541-545 Author Site , DOI
2011 'Erratum and Addendum to “Expression of PINK1 in the brain, eye and ear of mouse during embryonic development” [J. Chem. Neuroanat. 41 (2) (2011) 73–85]' Journal of Chemical Neuroanatomy 42, (1) 99-100 , DOI
Shelkovnikova TA, Ustyugov AA, Millership S, Peters O, Anichtchik O, Spillantini MG, Buchman VL, Bachurin SO & Ninkina NN 2011 'Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice' Neurodegener Dis 8, (6) 430-437 Author Site , DOI
Garcia-Reitböck P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E, Ghetti B, Della Corte L, Spano P & Tofaris GK 2010 'SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease' Brain 133, (Pt 7) 2032-2044 Author Site , DOI
Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG & Reichmann H 2010 'Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice' PLoS One 5, (1) Author Site , DOI
Jin CY, Anichtchik O & Panula P 2009 'Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases' Br J Pharmacol 157, (1) 118-129 Author Site , DOI
Sallinen V, Sundvik M, Reenilä I, Peitsaro N, Khrustalyov D, Anichtchik O, Toleikyte G, Kaslin J & Panula P 2009 'Hyperserotonergic phenotype after monoamine oxidase inhibition in larval zebrafish' J Neurochem 109, (2) 403-415 Author Site , DOI
Diekmann H, Anichtchik O, Fleming A, Futter M, Goldsmith P, Roach A & Rubinsztein DC 2009 'Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish' J Neurosci 29, (5) 1343-1349 Author Site , DOI
Anichtchik O, Diekmann H, Fleming A, Roach A, Goldsmith P & Rubinsztein DC 2008 'Loss of PINK1 function affects development and results in neurodegeneration in zebrafish' J Neurosci 28, (33) 8199-8207 Author Site , DOI
Peitsaro N, Sundvik M, Anichtchik OV, Kaslin J & Panula P 2007 'Identification of zebrafish histamine H1, H2 and H3 receptors and effects of histaminergic ligands on behavior' Biochem Pharmacol 73, (8) 1205-1214 Author Site , DOI
Anichtchik O, Sallinen V, Peitsaro N & Panula P 2006 'Distinct structure and activity of monoamine oxidase in the brain of zebrafish (Danio rerio)' J Comp Neurol 498, (5) 593-610 Author Site , DOI
Anichtchik OV, Kaslin J, Peitsaro N, Scheinin M & Panula P 2004 'Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine' J Neurochem 88, (2) 443-453 Author Site , DOI
Anichtchik OV, Kaslin J, Peitsaro N, Scheinin M & Panula P 2004 'Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine' JOURNAL OF NEUROCHEMISTRY 88, (2) 443-453 Author Site , DOI
Karlstedt K, Ahman MJ, Anichtchik OV, Soinila S & Panula P 2003 'Expression of the H3 receptor in the developing CNS and brown fat suggests novel roles for histamine' Mol Cell Neurosci 24, (3) 614-622 Author Site , DOI
Sallmen T, Lozada AF, Anichtchik OV, Beckman AL & Panula P 2003 'Increased brain histamine H3 receptor expression during hibernation in golden-mantled ground squirrels' BMC Neurosci 4, Author Site , DOI PEARL
Peitsaro N, Kaslin J, Anichtchik OV & Panula P 2003 'Modulation of the histaminergic system and behaviour by alpha-fluoromethylhistidine in zebrafish' J Neurochem 86, (2) 432-441 Author Site , DOI
Sallmen T, Lozada AF, Anichtchik OV, Beckman AL, Leurs R & Panula P 2003 'Changes in hippocampal histamine receptors across the hibernation cycle in ground squirrels' Hippocampus 13, (6) 745-754 Author Site , DOI
Rinne JO, Anichtchik OV, Eriksson KS, Kaslin J, Tuomisto L, Kalimo H, Röyttä M & Panula P 2002 'Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy' J Neurochem 81, (5) 954-960 Author Site , DOI
Lintunen M, Raatesalmi K, Sallmen T, Anichtchik O, Karlstedt K, Kaslin J, Kiianmaa K, Korpi ER & Panula P 2002 'Low brain histamine content affects ethanol-induced motor impairment' Neurobiol Dis 9, (1) 94-105 Author Site , DOI
Anichtchik OV, Peitsaro N, Rinne JO, Kalimo H & Panula P 2001 'Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease' Neurobiol Dis 8, (4) 707-716 Author Site , DOI
Anichtchik OV, Huotari M, Peitsaro N, Haycock JW, Männistö PT & Panula P 2000 'Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats' Eur J Neurosci 12, (11) 3823-3832 Author Site , DOI
Peitsaro N, Anichtchik OV & Panula P 2000 'Identification of a histamine H(3)-like receptor in the zebrafish (Danio rerio) brain' J Neurochem 75, (2) 718-724 Author Site , DOI
Anichtchik OV, Rinne JO, Kalimo H & Panula P 2000 'An altered histaminergic innervation of the substantia nigra in Parkinson's disease' Exp Neurol 163, (1) 20-30 Author Site , DOI
Panula P, Karlstedt K, Sallmen T, Peitsaro N, Kaslin J, Michelsen KA, Anichtchik O, Kukko-Lukjanov T & Lintunen M 2000 'The histaminergic system in the brain: structural characteristics and changes in hibernation' J Chem Neuroanat 18, (1-2) 65-74 Author Site , DOI
Zimatkin SM & Anichtchik OV 1999 'Alcohol-histamine interactions' Alcohol Alcohol 34, (2) 141-147 Author Site , DOI
Panula P, Sallmen T, Anichtchik O, Kuokkanen K, Lintunen M, Rinne JO, Mättö M, Kaslin J, Eriksson KS & Karlstedt K 1998 'Brain histamine in pathophysiological conditions and brain diseases' 243-253 , DOI
Anichtchik OV 2001 Histaminergic Regulation of the Nigrostriatal System in Parkinson's Disease and a Rat Model of Parkinsonism.
Evans T, Button R, Anichtchik O & Luo S 2018 'Visualization and Measurement of Multiple Components of the Autophagy Flux' Autophagy in Differentiation and Tissue Maintenance Springer New York 1-12 , DOI
Anichtchik O 1998 'The Histamine H3 Receptor' in Leurs R; Timmerman H The Histamine H3 Receptor Elsevier
Conference Papers
Koopman H, Jackson S, Anichtchik O & Carroll C 2015 'LPS INDUCES AGGREGATION OF α-SYNUCLEIN IN MONOCYTES' 1-/-0/1900 1-/-0/1900 BMJ e4.188-e4 , DOI
Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Gille G, Reichmann H, Spillantini MG & Funk RHW 2009 'Chronic oral administration of low doses of rotenone reproduces Braak's Parkinson's staging' 1-/-0/1900 1-/-0/1900 228-229
Pan-Montojo FJ, Anichtchik O, Dening YF, Pursche S, Gille G, Spillantini MG, Reichmann H & Funk RHW 2009 'Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice' 1-/-0/1900 1-/-0/1900 S42-S43
Salzmann J, Anichtchik O, Best J, Richards F, Fleming A, Roach A & Goldsmith P 2006 'P1 DEVELOPMENT OF A MPTP MODEL OF PARKINSON??S DISEASE IN ZEBRAFISH' 1-/-0/1900 1-/-0/1900 Ovid Technologies (Wolters Kluwer Health) 541-541 , DOI
Jin CY, Anichtchik OV, Peitsaro N, Lintunen M, Karlstedt K, Kalimo H & Panula P 2000 'mRNA expression of three histamine receptors in the human prefrontal cortex and thalamus' 1-/-0/1900 1-/-0/1900 409-409
Anichtchik OV, Peitsaro N, Rinne JO, Kalimo H & Panula P 2000 'The histaminergic innervation and histamine H3 receptors in basal ganglia of parkinsonian brains' 1-/-0/1900 1-/-0/1900 471-471